Reversal by RARα agonist Am580 of c-Myc-induced imbalance in RARα/RARγ expression during MMTV-Myc tumorigenesis.
about
The roles of retinoic acid and retinoic acid receptors in inducing epigenetic changesRetinoids induce cellular senescence in breast cancer cells by RAR-β dependent and independent pathways: Potential clinical implications (Review)NR2F1 controls tumour cell dormancy via SOX9- and RARβ-driven quiescence programmes.Cellular and molecular determinants of all-trans retinoic acid sensitivity in breast cancer: Luminal phenotype and RARα expression.Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer.microRNA-206 impairs c-Myc-driven cancer in a synthetic lethal manner by directly inhibiting MAP3K13.Activation of RARα induces autophagy in SKBR3 breast cancer cells and depletion of key autophagy genes enhances ATRA toxicity.Retinoic acid receptor gamma impacts cellular adhesion, Alpha5Beta1 integrin expression and proliferation in K562 cells.BCL-xL/MCL-1 inhibition and RARγ antagonism work cooperatively in human HL60 leukemia cells.Targeting the SIN3A-PF1 interaction inhibits epithelial to mesenchymal transition and maintenance of a stem cell phenotype in triple negative breast cancer.Cbx8 Acts Non-canonically with Wdr5 to Promote Mammary Tumorigenesis.Blocking the PAH2 domain of Sin3A inhibits tumorigenesis and confers retinoid sensitivity in triple negative breast cancerRetinoids and breast cancer: new clues to increase their activity and selectivity.Hypermethylation and loss of retinoic acid receptor responder 1 expression in human choriocarcinoma.Expression and Regulation of Retinoic Acid Receptor Responders in the Human Placenta.Therapeutic potential of Bcl-xL/Mcl-1 synthetic inhibitor JY-1-106 and retinoids for human triple-negative breast cancer treatment.Retinoic Acid, Leaky Gut, and Autoimmune Diseases
P2860
Q26866044-F61A65FE-30A4-487D-AEE7-B4E402CDEE0CQ28081010-0DCA6EBC-6C90-4194-A60D-06EF0197EFE3Q35037151-1DB53DA3-184F-419C-8D01-DF249D764DC8Q35904255-80ACC8B1-9CB0-4A2D-8887-93968B0B17B3Q35930608-19011F28-6A03-4F91-9DC5-F0EF37BD188FQ35937111-7D401E57-8530-4EB2-836E-876EABEF896CQ36022328-2F7815A1-C67C-4842-87FC-778445C86130Q36383862-84FB518B-215F-4E8E-BEFC-1198DD8FD248Q36504936-8C372070-AC33-49FD-B141-F8DC54BDC13FQ36544024-052A5E06-3F8C-4DD4-90D0-6AAD8BB07148Q37149776-A954FC18-D2D4-4464-86FE-CF6D143DEF39Q37536680-859ABABF-3229-458E-9E78-6F24459AD211Q42669872-6F76EB94-0205-4FCE-BE87-8650B8308C6DQ47110757-3DEF4CFE-0770-44A2-82AA-60AF2A43F2C0Q49805080-9551ACF3-1D39-456A-A58D-766D6E7EA25EQ55233805-FD4C49B3-1A1F-4023-BC24-E2D8F6434B3AQ58801064-B056D843-4B42-4E71-954A-41ECB0D7A86E
P2860
Reversal by RARα agonist Am580 of c-Myc-induced imbalance in RARα/RARγ expression during MMTV-Myc tumorigenesis.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Reversal by RARα agonist Am580 ...... during MMTV-Myc tumorigenesis.
@en
type
label
Reversal by RARα agonist Am580 ...... during MMTV-Myc tumorigenesis.
@en
prefLabel
Reversal by RARα agonist Am580 ...... during MMTV-Myc tumorigenesis.
@en
P2093
P2860
P356
P1476
Reversal by RARα agonist Am580 ...... during MMTV-Myc tumorigenesis.
@en
P2093
Alexis M Jones
Almudena Bosch
Avalon Garcia
Eduardo F Farias
Marcia I Dawson
Silvina P Bertran
P2860
P2888
P356
10.1186/BCR3247
P577
2012-08-24T00:00:00Z
P5875
P6179
1038073497